Compare CAPR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | PACB |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 696.3M |
| IPO Year | 2011 | 2010 |
| Metric | CAPR | PACB |
|---|---|---|
| Price | $7.60 | $1.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $27.25 | $2.74 |
| AVG Volume (30 Days) | 4.2M | ★ 12.7M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.77 | $14.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $2.96 | $1.07 |
| 52 Week High | $40.37 | $3.44 |
| Indicator | CAPR | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 36.02 |
| Support Level | $7.78 | $1.61 |
| Resistance Level | $10.62 | $1.83 |
| Average True Range (ATR) | 1.18 | 0.22 |
| MACD | -0.11 | -0.09 |
| Stochastic Oscillator | 19.61 | 1.42 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.